PSMD8

Across TCGA pan-cancer cohorts, PSMD8 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PSMD8 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PSMD8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PSMD8 expression acts as an unfavorable survival marker.

CESC, LUAD, and LIHC are the cancer types where PSMD8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	24	view →
LUAD	OS	Median	II,III,IV	0.141	0.709	<.001	18	view →
LIHC	OS	Median	II,III,IV	0.010	0.716	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PSMD8–CESC (OS)

Open the CESC breakdown →